SIREN : 819186560
SPFPL PHARMA-SANTE is a French company founded 10 years ago, specialized in the sector Activités des sociétés holding. Based in ERMONT (95120), this company of category PME shows in 2024 a net income positive of 74 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | N/C | N/C | N/C | N/C | N/C | N/C | N/C |
| Net income | 74 239 € | 73 344 € | 69 613 € | -34 405 € | -38 209 € | -44 263 € | -134 586 € |
| EBITDA | -6 769 € | -3 934 € | -3 997 € | -3 889 € | -4 131 € | -4 037 € | -94 597 € |
| Net margin | N/C | N/C | N/C | N/C | N/C | N/C | N/C |
In 2024, SPFPL PHARMA-SANTE generates positive net income of 74 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.
-6 769 €
-6 769 €
74 239 €
The debt ratio (= Financial debt / Equity x 100) stands at -2235%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches -3%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 22.7 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high.
-2235.163%
-2.789%
22.685
In 2024, the debt ratio of SPFPL PHARMA-SANTE (-2235.16) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2024, the financial autonomy of SPFPL PHARMA-SANTE (-2.8%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of SPFPL PHARMA-SANTE (22.68) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 0.07. Alert: short-term debt exceeds current assets. Risk of payment difficulties without cash reinforcement.
0.073
-288.108
In 2024, the liquidity ratio of SPFPL PHARMA-SANTE (0.07) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
In 2024, the interest coverage of SPFPL PHARMA-SANTE (-288.1x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 97 days. Excellent situation: suppliers finance 97 days of the operating cycle (retail model).
0 €
0 j
97 j
0 j
Based on 54 transactions of similar company sales
in 2024,
the value of SPFPL PHARMA-SANTE is estimated at
108 386 €
(range 69 126€ - 554 451€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Only this financial indicator is available for this company.
This estimate is based on the analysis of 54 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare SPFPL PHARMA-SANTE with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sociétés holding
The revenue of SPFPL PHARMA-SANTE is not publicly disclosed (confidential accounts filed with INPI).
Yes, SPFPL PHARMA-SANTE generated a net profit of 74 k€ in 2024.
The headquarters of SPFPL PHARMA-SANTE is located in ERMONT (95120), in the department Val-d'Oise.
The tax return of SPFPL PHARMA-SANTE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
SPFPL PHARMA-SANTE operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.